CytomX Shares Rise After Trial Progress CytomX (CTMX) drew analyst attention on Mar 27, 2026 after progress in a Phase 1 program; institutional investors should watch upcoming readouts and funding runway closely.

CytomX Shares Rise After Trial Progress: CytomX (CTMX) drew analyst attention on Mar 27, 2026 after progress in a Phase 1 program; institutional investors should watch upcoming readouts and funding runway closely. 👈 Read full analysis #CytomX #CTMX #Pharmaceuticals #Investing #ClinicalTrials

Biogen Shares Rise After Positive Litifilimab Phase 2 CLE Data Biogen reported a second positive Phase 2 litifilimab result at Week 16; data presented Mar 28, 2026 (source: Business Insider/GlobeNewswire).

Biogen Shares Rise After Positive Litifilimab Phase 2 CLE Data: Biogen reported a second positive Phase 2 litifilimab result at Week 16; data presented Mar 28, 2026 (source: Business Insider/GlobeNewswire). 👈 Read full analysis #Biogen #Litifilimab #Phase2ClinicalTrial #Pharmaceuticals #Healthcare

BioCryst 2025 Slides Map Path to $1B BioCryst's 2025 slides set a $1.0bn revenue target; Investing.com reported on Mar 28, 2026, signalling portfolio shifts and Navenibart expansion that warrant reworked models.

BioCryst 2025 Slides Map Path to $1B: BioCryst's 2025 slides set a $1.0bn revenue target; Investing.com reported on Mar 28, 2026, signalling portfolio shifts and Navenibart expansion that warrant reworked… 👈 Read full analysis #BioCryst #RevenueGrowth #Pharmaceuticals #Investing #MarketAnalysis

Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025 Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2 filings.

Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025: Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2… 👈 Read full analysis #PumaBiotechnology #Nerlynx #Q42025 #Pharmaceuticals #BiotechInvesting

Viagra remains one of the most widely recognized pharmaceutical products, helping men all around the world think they still got it.

Follow the page for more daily history!

#Viagra #FDA #MedicalHistory #Pfizer #Healthcare #Pharmaceuticals

PlaneAlert ICAO: AB3966 Tail: N822MK Flt: N822MK
Owner: MerckGroup
Aircraft: Gulfstream G650
2026-03-27 14:39:54 CDT
G650 Civ Pharmaceuticals Vaccines Bizjet AsSeenonTV
- wiki - adsbexchange

Autolus Reiterates $120M–$135M AUCATZYL 2026 Target Autolus reiterated a $120M–$135M 2026 revenue target for AUCATZYL on Mar. 27, 2026 and said it will expand its pivotal-trial program (Seeking Alpha).

Autolus Reiterates $120M–$135M AUCATZYL 2026 Target: Autolus reiterated a $120M–$135M 2026 revenue target for AUCATZYL on Mar. 27, 2026 and said it will expand its pivotal-trial program (Seeking Alpha). 👈 Read full analysis #Autolus #AUCATZYL #Biotech #Pharmaceuticals #ClinicalTrials

PlaneAlert ICAO: A6FF7F Tail: N550AV Flt: N550AV
Owner: AbbvieUS
Aircraft: Gulfstream G550
2026-03-27 10:41:17 CDT
GLF5 Civ Bizjet Biotech Pharmaceuticals AsSeenonTV
- wiki - adsbexchange

Eli Lilly $1,300 Target Reiterated by Jefferies Jefferies reiterated Buy on Eli Lilly with a $1,300 12-month target on Mar 27, 2026 (Investing.com); the note pins value to GLP‑1 franchise strength and upcoming late‑stage readouts.

Eli Lilly $1,300 Target Reiterated by Jefferies: Jefferies reiterated Buy on Eli Lilly with a $1,300 12-month target on Mar 27, 2026 (Investing.com); the note pins value to GLP‑1 franchise strength and… 👈 Read full analysis #EliLilly #Investing #StockMarket #HealthcareInvesting #Pharmaceuticals

ORIC Pharmaceuticals to Report Prostate Trial Data Tuesday ORIC (NASDAQ: ORIC) will publish prostate cancer cohort data on Tuesday, Mar 31, 2026 (Investing.com); this binary readout could move valuation by ±25% or more.

ORIC Pharmaceuticals to Report Prostate Trial Data Tuesday: ORIC (NASDAQ: ORIC) will publish prostate cancer cohort data on Tuesday, Mar 31, 2026 (Investing.com); this binary readout could move valuation by ±25% or… 👈 Read full analysis #ORIC #ProstateCancer #Biotech #ClinicalTrials #Pharmaceuticals

PlaneAlert ICAO: A6FF7F Tail: N550AV
Owner: AbbvieUS
Aircraft: Gulfstream G550
2026-03-27 07:42:38 EDT
GLF5 Bizjet Biotech Pharmaceuticals AsSeenonTV
adsb - wiki - adsbexchange

Revolutionizing Pharmaceutical Carbon Neutrality with Shared EV Charging Infrastructure A new collaborative EV charging model in the pharmaceutical sector helps achieve carbon neutrality while supporting electric vehicle adoption among medical reps.

Revolutionizing Pharmaceutical Carbon Neutrality with Shared EV Charging Infrastructure #Japan #Tokyo #pharmaceuticals #CarbonNeutrality #SharedEVCharging

Well hello there 👀☕
#StockMarket #Stocks #Pharmaceuticals

Hey so, what's this huh? 👀 #Biotech #TheIsland #Pharmaceuticals #Bioengineering #Cloning #Cryogenics

PlaneAlert ICAO: A6FF7F Tail: N550AV
Owner: AbbvieUS
Aircraft: Gulfstream G550
2026-03-26 11:44:16 EDT
GLF5 Bizjet Biotech Pharmaceuticals AsSeenonTV
adsb - wiki - adsbexchange

Original post on newsie.social

Inside The Turmoil at #RobertFKennedyJr #CDC 43 current and former C.D.C. employees on the changes they say are replacing #science with #ideology making Americans more vulnerable. NYT Gift Article "The civil servants who spoke to me worry that, instead, a century’s worth of expertise is being […]

Armata Pharmaceuticals Posts GAAP Loss of $3.42 Armata reported GAAP EPS -$3.42 and revenue $1.1M on Mar 26, 2026 (Seeking Alpha); results heighten focus on cash runway and upcoming clinical milestones.

Armata Pharmaceuticals Posts GAAP Loss of $3.42: Armata reported GAAP EPS -$3.42 and revenue $1.1M on Mar 26, 2026 (Seeking Alpha); results heighten focus on cash runway and upcoming clinical milestones. 👈 Read full analysis #Pharmaceuticals #Healthcare #Investing #ClinicalTrials #GAAP

The Blood Pressure Paradox: Why Lowering Your Numbers Could Be Dangerous In today's episode we're uncovering the "Blood Pressure Paradox" and why the modern medical push for ever-lower targets may actually be doing more harm than good. We explore how shifting guidelines have turned nearly half of all American adults into "hypertensive" patients overnight, often based on variable or incorrect measurements. You will learn why high blood pressure may actually be a vital compensatory response to maintain blood flow to the brain and kidneys rather than a primary disease. We also dive into the hidden risks of over-medication, including increased mortality, falls, and kidney injury,. References: - https://www.forgottenmedicine.com/p/understanding-blood-pressure-in-a-healthy-way - https://www.forgottenmedicine.com/ Support our work. Make a small donation. Support our work. Make a small donation. This removes any advertisements and help us continue bringing more interesting topics and confronting mainstream narrative on health. Click the Link to support us:https://www.spreaker.com/podcast/foodnourish-deep-dives--6602003/support

📣 New Podcast! "The Blood Pressure Paradox: Why Lowering Your Numbers Could Be Dangerous" on @Spreaker #arteries #atherosclerosis #blood #cardiology #circulation #diuretics #doctors #guidelines #health #hypertension #longevity #medicine #nutrition #pharmaceuticals #pressure #research #safety

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline Merck is acquiring Terns Pharmaceuticals for $6.7 billion to enhance its cancer drug pipeline. The d...

Merck is acquiring Terns Pharmaceuticals for $6.7 billion to enhance its cancer drug pipeline. The deal, announced Wednesday, aims to bolster Merck's portfolio before key patent expirations. #pharmaceuticals #News

Celcuity Forecasts $2.5B Peak Revenue for Gedatolisib Celcuity projects $2.5B peak revenue for gedatolisib with pivotal readouts in 2026–27 and commercial steps underway (Seeking Alpha, Mar 26, 2026).

Celcuity Forecasts $2.5B Peak Revenue for Gedatolisib: Celcuity projects $2.5B peak revenue for gedatolisib with pivotal readouts in 2026–27 and commercial steps underway (Seeking Alpha, Mar 26, 2026). 👈 Read full analysis #Celcuity #Gedatolisib #Pharmaceuticals #Biotechnology #MarketForecast

Tivic Health Targets $20B Oncology Market After Pivot Tivic Health projects a $20B oncology opportunity (reported Mar 25, 2026); realization hinges on clinical readouts, payer coverage and financing over the next 2–5 years.

Tivic Health Targets $20B Oncology Market After Pivot: Tivic Health projects a $20B oncology opportunity (reported Mar 25, 2026); realization hinges on clinical readouts, payer coverage and financing… 👈 Read full analysis #Oncology #HealthTech #CancerResearch #Pharmaceuticals #HealthcareInnovation

Merck to Buy Terns for $6.7B Merck agreed to acquire Terns for $6.7B on Mar 25, 2026 (Bloomberg); the deal is a focused bet on a leukemia asset as Merck seeks pipeline replenishment.

Merck to Buy Terns for $6.7B: Merck agreed to acquire Terns for $6.7B on Mar 25, 2026 (Bloomberg); the deal is a focused bet on a leukemia asset as Merck seeks pipeline replenishment. 👈 Read full analysis #Merck #TernsPharmaceuticals #Acquisition #Leukemia #Pharmaceuticals

Merck Pays $6.7B for Terns, Investors Question Premium Merck's $6.7B cash bid for Terns Pharma (Mar 25, 2026) implies an estimated 70–80% premium to recent trading, raising questions about valuation and integration timelines.

Merck Pays $6.7B for Terns, Investors Question Premium: Merck's $6.7B cash bid for Terns Pharma (Mar 25, 2026) implies an estimated 70–80% premium to recent trading, raising questions about valuation and… 👈 Read full analysis #Merck #TernsPharma #Pharmaceuticals #MergersAndAcquisitions #Investing

🇪🇺 EU definitive anti-dumping duty on phosphorous acid
👮 Duty imposed is 122.8%
🌏 Origin: China
🔗 zurl.co/0hSRO

#Chemicals #Construction #Agriculture #Textile #Pharmaceuticals

Original post on spacey.space

RE: https://mstdn.social/@TechCrunch/116205018327360404

A reliable technology for returning payloads to Earth from #space 🌌 is a necessity for several futuristic business models — testing new materials in orbit, manufacturing #pharmaceuticals 💊 or high-end #electronics in microgravity, or […]

Depression doesn't exist? How to become happy. Come in, have a seat.

For now read my article about depression, and help those who are in need.

Big pharma normalized antidepressants, and nowadays we see people taking it like candies.

This person is a life-time subscriber, and you’ve been lie about it, it’s far worse than you think.
#neuroscience #pharmaceuticals

PlaneAlert ICAO: AB3966 Tail: N822MK Flt: N822MK
Owner: MerckGroup
Aircraft: Gulfstream G650
2026-03-25 08:43:23 EDT
G650 Pharmaceuticals Vaccines Bizjet AsSeenonTV
adsb - wiki - adsbexchange

Merck Buys Terns for $6.7bn to Fortify Oncology Merck will acquire Terns for $6.7bn (announced Mar 25, 2026) as Keytruda faces patent loss in 2028; the deal recalibrates Merck's oncology pipeline strategy.

Merck Buys Terns for $6.7bn to Fortify Oncology: Merck will acquire Terns for $6.7bn (announced Mar 25, 2026) as Keytruda faces patent loss in 2028; the deal recalibrates Merck's oncology pipeline… 👈 Read full analysis #Merck #TernsPharmaceuticals #Oncology #Pharmaceuticals #MergersAndAcquisitions

#Wednesday #WednesdayVibes #HumpDay #4040rec #medicalsalesjobs #BusinessDevelopment #commercial #territorymanagement #marketaccess #marketing #leadership #peoplemanagement #pharmaceuticals #firstlinemanagement #internalsales #telesales #accountmanagement #healthcare #medtech #biotech #healthtech

PlaneAlert ICAO: AB3966 Tail: N822MK Flt: N822MK
Owner: MerckGroup
Aircraft: Gulfstream G650
2026-03-24 19:20:20 EDT
G650 Pharmaceuticals Vaccines Bizjet AsSeenonTV
adsb - wiki - adsbexchange